Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility in Melbourne, Australia.

The two leading nuclear medicine enterprises have come together to develop, manufacture and supply the next generation of therapeutic radiopharmaceuticals for cancer treatments.

The new company Applied Molecular Therapies Pty Ltd (AMT) will aim to establish a Therapeutic Goods Administration (TGA) approved, GMP manufacturing capability for a range of radiopharmaceutical therapies, initially focused on use of the radionuclide Lutetium-177.

To read more please visit:

New Joint Venture to manufacture GMP theranostic radiopharmaceuticals  in  Australia

Source: ANSTO